191 related articles for article (PubMed ID: 22749643)
41. Towards discovery of new leishmanicidal scaffolds able to inhibit
Martínez de Iturrate P; Sebastián-Pérez V; Nácher-Vázquez M; Tremper CS; Smirlis D; Martín J; Martínez A; Campillo NE; Rivas L; Gil C
J Enzyme Inhib Med Chem; 2020 Dec; 35(1):199-210. PubMed ID: 31752556
[TBL] [Abstract][Full Text] [Related]
42. Structure-activity relationship (SAR) studies of synthetic glycogen synthase kinase-3β inhibitors: A critical review.
Xu M; Wang SL; Zhu L; Wu PY; Dai WB; Rakesh KP
Eur J Med Chem; 2019 Feb; 164():448-470. PubMed ID: 30616053
[TBL] [Abstract][Full Text] [Related]
43. Discovery of new GSK-3β inhibitors through structure-based virtual screening.
Dou X; Jiang L; Wang Y; Jin H; Liu Z; Zhang L
Bioorg Med Chem Lett; 2018 Jan; 28(2):160-166. PubMed ID: 29208522
[TBL] [Abstract][Full Text] [Related]
44. Design and synthesis of 3-(4-pyridyl)-5-(4-sulfamido-phenyl)-1,2,4-oxadiazole derivatives as novel GSK-3β inhibitors and evaluation of their potential as multifunctional anti-Alzheimer agents.
Wang M; Liu T; Chen S; Wu M; Han J; Li Z
Eur J Med Chem; 2021 Jan; 209():112874. PubMed ID: 33017743
[TBL] [Abstract][Full Text] [Related]
45. Glycogen synthase kinase-3 and its inhibitors: Potential target for various therapeutic conditions.
Saraswati AP; Ali Hussaini SM; Krishna NH; Babu BN; Kamal A
Eur J Med Chem; 2018 Jan; 144():843-858. PubMed ID: 29306837
[TBL] [Abstract][Full Text] [Related]
46. A novel GSK-3 inhibitor binds to GSK-3β via a reversible, time and Cys-199-dependent mechanism.
Ghazanfari D; Noori MS; Bergmeier SC; Hines JV; McCall KD; Goetz DJ
Bioorg Med Chem; 2021 Jun; 40():116179. PubMed ID: 33991821
[TBL] [Abstract][Full Text] [Related]
47. Synthesis of benzimidazole-linked-1,3,4-oxadiazole carboxamides as GSK-3β inhibitors with in vivo antidepressant activity.
Tantray MA; Khan I; Hamid H; Alam MS; Dhulap A; Kalam A
Bioorg Chem; 2018 Apr; 77():393-401. PubMed ID: 29421716
[TBL] [Abstract][Full Text] [Related]
48. Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors.
Luo G; Chen L; Burton CR; Xiao H; Sivaprakasam P; Krause CM; Cao Y; Liu N; Lippy J; Clarke WJ; Snow K; Raybon J; Arora V; Pokross M; Kish K; Lewis HA; Langley DR; Macor JE; Dubowchik GM
J Med Chem; 2016 Feb; 59(3):1041-51. PubMed ID: 26751161
[TBL] [Abstract][Full Text] [Related]
49. Role of glycogen synthase kinase-3 in Alzheimer's disease pathogenesis and glycogen synthase kinase-3 inhibitors.
Avila J; Wandosell F; Hernández F
Expert Rev Neurother; 2010 May; 10(5):703-10. PubMed ID: 20420491
[TBL] [Abstract][Full Text] [Related]
50. The active form of glycogen synthase kinase-3beta is associated with granulovacuolar degeneration in neurons in Alzheimer's disease.
Leroy K; Boutajangout A; Authelet M; Woodgett JR; Anderton BH; Brion JP
Acta Neuropathol; 2002 Feb; 103(2):91-9. PubMed ID: 11810173
[TBL] [Abstract][Full Text] [Related]
51. GSK-3 inhibitors for Alzheimer's disease.
Avila J; Hernández F
Expert Rev Neurother; 2007 Nov; 7(11):1527-33. PubMed ID: 17997701
[TBL] [Abstract][Full Text] [Related]
52. The optimization of aminooxadiazoles as orally active inhibitors of Cdc7.
Harrington PE; Bourbeau MP; Fotsch C; Frohn M; Pickrell AJ; Reichelt A; Sham K; Siegmund AC; Bailis JM; Bush T; Escobar S; Hickman D; Heller S; Hsieh F; Orf JN; Rong M; San Miguel T; Tan H; Zalameda L; Allen JG
Bioorg Med Chem Lett; 2013 Dec; 23(23):6396-400. PubMed ID: 24120542
[TBL] [Abstract][Full Text] [Related]
53. Inhibition of glycogen synthase kinase by curcumin: Investigation by simulated molecular docking and subsequent in vitro/in vivo evaluation.
Bustanji Y; Taha MO; Almasri IM; Al-Ghussein MA; Mohammad MK; Alkhatib HS
J Enzyme Inhib Med Chem; 2009 Jun; 24(3):771-8. PubMed ID: 18720192
[TBL] [Abstract][Full Text] [Related]
54. Molecular dynamics simulation studies of GSK-3β ATP competitive inhibitors: understanding the factors contributing to selectivity.
Arfeen M; Patel R; Khan T; Bharatam PV
J Biomol Struct Dyn; 2015; 33(12):2578-93. PubMed ID: 26209183
[TBL] [Abstract][Full Text] [Related]
55. Pharmacological inhibitors of glycogen synthase kinase 3.
Meijer L; Flajolet M; Greengard P
Trends Pharmacol Sci; 2004 Sep; 25(9):471-80. PubMed ID: 15559249
[TBL] [Abstract][Full Text] [Related]
56. Biosynthesis of new indigoid inhibitors of protein kinases using recombinant cytochrome P450 2A6.
Wu ZL; Aryal P; Lozach O; Meijer L; Guengerich FP
Chem Biodivers; 2005 Jan; 2(1):51-65. PubMed ID: 17191919
[TBL] [Abstract][Full Text] [Related]
57. Triazolo[1,5-a]pyrimidines as novel CDK2 inhibitors: protein structure-guided design and SAR.
Richardson CM; Williamson DS; Parratt MJ; Borgognoni J; Cansfield AD; Dokurno P; Francis GL; Howes R; Moore JD; Murray JB; Robertson A; Surgenor AE; Torrance CJ
Bioorg Med Chem Lett; 2006 Mar; 16(5):1353-7. PubMed ID: 16325401
[TBL] [Abstract][Full Text] [Related]
58. Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools.
Perez DI; Conde S; Pérez C; Gil C; Simon D; Wandosell F; Moreno FJ; Gelpí JL; Luque FJ; Martínez A
Bioorg Med Chem; 2009 Oct; 17(19):6914-25. PubMed ID: 19747834
[TBL] [Abstract][Full Text] [Related]
59. Development of a cellular tau enzyme-linked immunosorbent assay method for screening GSK-3β inhibitors.
Cho GW; Noh MY; Kang BY; Ku IW; Park J; Hong YH; Kim MH; Kim SH
Assay Drug Dev Technol; 2011 Oct; 9(5):503-13. PubMed ID: 21561378
[TBL] [Abstract][Full Text] [Related]
60. Rational design of 4-amino-5,6-diaryl-furo[2,3-d]pyrimidines as potent glycogen synthase kinase-3 inhibitors.
Miyazaki Y; Maeda Y; Sato H; Nakano M; Mellor GW
Bioorg Med Chem Lett; 2008 Mar; 18(6):1967-71. PubMed ID: 18280153
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
